Nurix Therapeutics Announces Scientific Presentations on its BTK Program at the 61st American Society of Hematology Annual Meeting
SAN FRANCISCO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc., a company developing novel therapies that control disease-causing proteins, today announced an oral presentation on its wholly-owned, BTK degrader program for chronic lymphocytic leukemia will be delivered by the Company’s collaborators from the National Institutes of Health at the upcoming 61st American Society of Hematology meeting (ASH). A poster presentation will also be presented on the BTK degradation mechanism of action. ASH is being held on December 7-10, 2019 at the Orange County Convention Center in Orlando, Fla.
Oral Presentation Details:
| Title: | Highly Potent BTK Degradation Induced by NRX0492 As a Therapeutic Strategy for CLL | |
| Session: | 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases I Hematology Disease Topics & Pathways: Diseases, Leukemia, Biological, Therapies, CLL, immune cells, Lymphoid Malignancies, TKI Presenter: Deyi Zhang, Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH, Bethesda, MD |
|
| Date: | Saturday, December 7, 2019 | |
| Time: | 1:15 p.m. EST | |
| Location: | W414AB, Level 4 | |
Poster Presentation Details:
| Title: | Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies | |
| Session: | 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster III Hematology Disease Topics & Pathways: Diseases, Leukemia, Biological, Therapies, CLL, immune cells, Lymphoid Malignancies, TKI |
|
| Date: | Monday, December 9, 2019 | |
| Time: | 6:00 – 8:00 p.m. EST | |
| Location: | Hall B, Level 2 | |
About Nurix Therapeutics
Nurix Therapeutics develops novel therapies that control disease-causing proteins. Nurix’s pipeline is focused on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com.
Media Contact
Sara Zelkovic
LifeSci Public Relations
Sara@lifescipublicrelations.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
